Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MSC to Prevent and Treat Rejection After Renal Transplantation
NCT02490020Phase 1Unknown
- Start
- Jan 2016
- Primary completion
- Dec 2016
- Modality
- Stem Cell Therapies
01
Overview
Phase 1, randomised, open-label trial of mesenchymal stem cells in renal transplant rejection (RTR) and delayed graft function (DGF) (8 arms). Primary endpoints: Numbers of participants enrolled into the MSC group and control group at 1 year, Incident rates of Biopsy Proven Acute Rejection (BPAR) at 1 year and 1 more. Status: unknown.
02
Drugs
mesenchymal stem cells
03
Conditions
renal transplant rejection (RTR)delayed graft function (DGF)
Beyond the preview
Go deeper on NCT02490020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02490020.